Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

16    Mylan    $5.6B    up 16.7%
Global revenue: $6.1B (19th); up 10.9%

R&D spend: $282M (20th), up 4.6%; 4.8% of rev.

Top brands: Fentanyl ($472M), bupropion XL ($336M), omeprazole Rx ($242M), EpiPen ($226M)

Planned launches: Generic versions of Advair Diskus (resp.)

Promotional spend: $2M (20th); 0.04% of rev.

Patent expirations: N/A

Five years ago, the Pittsburgh generics giant cobbled together an empire through its acquisitions of Dey Pharma, Matrix Laboratories and the Merck KGaA generics business, going from being the No. 3 player in US generics to No. 3 worldwide. Now Mylan is looking to expand in markets where generics are underutilized, including much of Europe, the Middle East and Asia (half the company's revenues come from generics-happy North America), while increasing the number of products it markets from 4,700 to 6,700 by 2015 and pushing into generic biologics. The firm faces some generic erosion of its own, though, as Sanofi and Intelliject will launch a competitor to its lucrative EpiPen Auto-Injector franchise in November.

Back to first page

Page 16 of 21
Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"